Clozapine, Smoking Cessation, and Cannabis in Schizophrenia
Mr. K is a 38-year-old man with schizophrenia, stable on clozapine 400 mg/day for 4 years, and cannabis use disorder (daily). He smokes 30 cigarettes/day and wants to quit after his apartment building bans smoking. His clozapine level is 480 ng/mL (therapeutic 350-600) and ANC is normal. He has no prior seizures. He asks about varenicline. The clinic has a cessation program but limited ability to check clozapine levels more than weekly. He has Medicaid and no reliable phone. He has tried nicotine gum once and disliked it.
1. Why does stopping smoking change clozapine levels, and what monitoring plan would you use given weekly level access?
Read the worked answer
Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), not nicotine, that induce CYP1A2, the main enzyme metabolizing clozapine. While smoking, clearance is increased; when smoking stops, induction resolves over roughly one to two weeks, so clozapine levels rise and toxicity risk increases (sedation, orthostasis, seizures, constipation, sialorrhea). Because levels can only be checked weekly, reduce the clozapine dose preemptively by about 20-30% at the quit date, or monitor daily symptoms and use the first weekly level to guide adjustment.
Check a level 5-7 days after cessation and again if symptoms change. Do not start a strong CYP1A2 inhibitor such as fluvoxamine or ciprofloxacin during this period. Cannabis smoking also produces PAHs, so stopping cannabis could further raise clozapine levels; ask about changes. Educate the patient about warning symptoms and ensure ANC monitoring continues. Coordinate with the clozapine clinic and pharmacy; abrupt smoking cessation without dose adjustment is the main hazard.
2. Compare varenicline, bupropion, and nicotine replacement for this patient.
Read the worked answer
Varenicline is first-line and effective in people with schizophrenia; it is renally cleared and has no major CYP interaction with clozapine. Monitor mood, sleep, and psychotic symptoms, but do not withhold it because of older neuropsychiatric warnings. Bupropion is also effective, but it lowers seizure threshold and clozapine does too; it inhibits CYP2D6 and may interact with other medications. It could be considered if varenicline fails and seizures are not a concern, but I would avoid it first-line here.
Nicotine replacement, especially a patch plus short-acting lozenge, is safe and does not affect clozapine levels; his dislike of gum does not preclude a patch or lozenge. Choice should reflect adherence, cost, and preference. All cessation medications should be paired with behavioral counseling. The key safety issue is the clozapine level, not the cessation drug itself.
3. How would you address his daily cannabis use alongside tobacco cessation?
Read the worked answer
Treat tobacco cessation as the priority but do not ignore cannabis. Use motivational interviewing and ask what cannabis does for him; many patients use it for sleep, anxiety, or psychosis-related distress. Cannabis can worsen psychosis and may reduce clozapine adherence. Contingency management and CBT are evidence-based for cannabis use disorder.
If he stops cannabis as well as tobacco, clozapine levels may rise further because PAH exposure falls; monitor closely and adjust the dose. Do not make cannabis abstinence a precondition for nicotine treatment. If he continues cannabis, that does not justify stopping tobacco cessation. Coordinate with his mental health team, provide psychoeducation about the interaction, and avoid punitive urine testing. Set small, measurable goals and follow up frequently.